RT Journal Article
SR Electronic
T1 Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1607
OP 1613
DO 10.21873/anticanres.15635
VO 42
IS 3
A1 TAKURO OKADA
A1 CHIHIRO FUSHIMI
A1 TAKASHI MATSUKI
A1 ISAKU OKAMOTO
A1 HIROKI SATO
A1 TAKAHITO KONDO
A1 KUNIHIKO TOKASHIKI
A1 TAKUMA KISHIDA
A1 TATSUYA ITO
A1 GAI YAMASHITA
A1 YUSUKE AIHARA
A1 KENJI HANYU
A1 YUKIOMI KUSHIHASHI
A1 TATSUO MASUBUCHI
A1 YUICHIRO TADA
A1 KOUKI MIURA
A1 YUKI HARADA
A1 KAHO MOMIYAMA
A1 TAKU YAMASHITA
A1 GO OMURA
A1 HIDEAKI TAKAHASHI
A1 NOBUHIKO ORIDATE
A1 KIYOAKI TSUKAHARA
YR 2022
UL http://ar.iiarjournals.org/content/42/3/1607.abstract
AB Background/Aim: There are no real-world comparative data of nivolumab doses of 3 mg/kg and 240 mg/body for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). We investigated the efficacy and safety of nivolumab in treating recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) at different doses using real-world data. Patients and Methods: R/M SCCHN patients who received nivolumab were divided into the 3 mg/kg and 240 mg/body groups and retrospectively examined for efficacy and safety. Results: A total of 199 patients (3 mg/kg and 240 mg/body, 88 and 111 patients, respectively) were included. The 3 mg/kg vs. 240 mg/body groups had similar overall response rates (15% vs. 25, p=0.15), disease control rates (46% vs. 57%, p=0.15), overall survival (9.5 months vs. 10.9 months), and progression-free survival (3.7 months vs. 3.8 months, p=0.95). The incidence of immune-related adverse events was also similar in both groups. Conclusion: In R/M SCCHN patients, nivolumab showed similar efficacy and safety at doses of 3 mg/kg and 240 mg/body.